Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma. In a study published in Neuro-Oncology, the researchers show that reprogramming myeloid cells, a type of immune cell that glioblastoma tumors co-opt to protect…
CPRIT honors UTSW’s Argenbright with Texans Conquer Cancer Award: Newsroom UT Southwestern
FDA Approves Atezolizumab Plus Chemo for Stage 3 dMMR Colon Cancer Oncology Nursing News
National Cancer Institute director visits Fred Hutch Fred Hutchinson Cancer Research Center
Finding meaning in my stage 3 triple-negative breast cancer diagnosis UT MD Anderson
Surgical volume could be reduced for patients with locally advanced head and neck squamous cell carcinoma who respond to neoadjuvant chemoimmunotherapy. Data from a phase 2 trial showed individuals with HPV-negative disease, who achieved at least a 50% reduction in primary tumor burden after neoadjuvant treatment, and…
ALCMI and Sophos IRB Form Strategic Partnership to Advance Lung Cancer Clinical Research Yahoo Finance
Omar Abdihamid: Honored to Contribute to the Global Oncology Research Community Oncodaily
Panagiota Mitrou: New Evidence on the Changing Landscape of Early-Onset Cancer Oncodaily
Онколог рассказал, как ожирение связано с раком АБН24
Ashish Manne: Rethinking AI’s Role in Pancreatic Cancer Care Oncodaily
Xenofon Vakalis: ASTRO 2026 and the Changing Role of Radiotherapy in Bladder Cancer Oncodaily